Vivek Subbiah: Where does the AACR24 Plenary Chair work with the ASCO Plenary Chair?

Vivek Subbiah shared a post on LinkedIn:

“Where does the American Association for Cancer Research AACR24 Plenary Chair work with the American Society of Clinical Oncology (ASCO) ASCO24 Plenary Chair?

Thrilled to work alongside the world-renowned Dr. Melissa Johnson, my clinic day partner. as we have exhilarating discussions on Precision Medicine and picking rare gene fusion needles from the haystack. Dr. MJ picked one needle today.

Save the date: American Society of Clinical Oncology (ASCO) Plenary Series, April 30, 2024. Dr. Melissa Johnson Chairs the ASCO plenaries on KRAS G12C.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.